All told, who took GLP-1 receptor agonists had a 7% lower risk of developing an OAC – which include cancers of the oesophagus, colon, rectum, stomach, liver, gallbladder, pancreas, kidney, post ...

AstraZeneca and Bristol-Myers Squibb further expand their ongoing diabetes alliance, following the completion of Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals. Bristol-Myers ...

However, they also cause increased sodium and fluid retention, thereby leading to a 42% increased risk of incident heart failure.4 In contrast, dipeptidyl peptidase 4 inhibitors appear to have a ...

June 25, 2025 — A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner diversity. This insight could transform how we treat ...

N-Aryl-3,4-dihydroisoquinoline carbothioamide analogues 1–22 were synthesized by a simple one-step reaction protocol and subjected to in vitro urease inhibition studies for the first time. All ...